PT - JOURNAL ARTICLE AU - Vânia Gaio AU - Adriana Silva AU - Palmira Amaral AU - João Faro Viana AU - Pedro Pinto Leite AU - Carlos Matias Dias AU - Irina Kislaya AU - Baltazar Nunes AU - Ausenda Machado TI - COVID-19 vaccine effectiveness among healthcare workers in Portugal: results from a hospital-based cohort study, December 2020 to November 2021 AID - 10.1101/2022.01.07.22268889 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.07.22268889 4099 - http://medrxiv.org/content/early/2022/01/07/2022.01.07.22268889.short 4100 - http://medrxiv.org/content/early/2022/01/07/2022.01.07.22268889.full AB - Introduction Healthcare workers (HCW) were amongst the first prioritized for COVID-19 vaccination but data on COVID-19 vaccine effectiveness among HCW is still limited. This study aims to estimate the COVID-19 vaccine effectiveness (VE) against SARS-CoV-2 symptomatic infection among HCW from Portuguese hospitals.Methods In this prospective cohort study, we analysed data from HCW (all professional categories) from two central hospitals in the Lisbon and Tagus Valley and Centre regions of mainland Portugal between December 2020 and November 2021. VE against symptomatic SARS-CoV-2 infection was estimated as one minus the confounder adjusted hazard ratios by Cox models considering age group, sex, presence of chronic disease and occupational exposure to patients diagnosed with COVID-19 as adjustment variables.Results During the 11 months of follow up, the 2213 HCW contributed a total of 1950 person-years at risk and 171 SARS-CoV-2 events occurred. The COVID-19 incidence rate for unvaccinated HCW was 348.7 per 1000 person-years while for fully vaccinated HCW was 43.0 per 1000 person-years. We observed a VE against symptomatic SARS-CoV-2 infection of 73.9% (95% CI: 26.2–90.8%) for complete vaccination status.Conclusion This cohort study found a high COVID-19 VE against symptomatic SARS-CoV-2 infection in Portuguese HCW, which is in concordance with previous studies from other countries. Monitoring of VE in this HCW cohort continues during the winter 2021/2022 to evaluate potential VE decay and booster vaccine effect.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by ECDC (Contract ECD.11486 Developing an infrastructure and performing vaccine effectiveness studies for COVID-19 vaccine in the EU/EEA Lot3 (HCW)).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data were anonymised before statistical analysis by the occupational health services of each hospital. This study protocol was approved by the ethics committee of the Instituto Nacional de Saude Doutor Ricardo Jorge (date of approval. 16/04/2021), and by the ethics committees of the two participating hospitals, namely by the ethics committee of CHTV (Ref.06/16/04/2021, date of approval 16/04/2021) and CHLO (Ref. 2141, date of approval 19/05/2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors